Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT05426317 Recruiting - Melanoma Clinical Trials

Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression

Onco-PDL1s/B2M
Start date: February 10, 2022
Phase: N/A
Study type: Interventional

Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course of a metastatic solid tumor treated with a first-line therapeutic of checkpoint immune inhibitor.

NCT ID: NCT05407441 Not yet recruiting - Chordoma Clinical Trials

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: - Tazemetostat (TAZVERIK) - Nivolumab (OPDIVO) - Ipilimumab (YERVOY)

NCT ID: NCT05404685 Not yet recruiting - Clinical trials for Kidney Tumors Treated With Minimally Invasive Surgery

Partial Nephrectomy in Low Pressure

P-NeLoP
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The main objective is to prospectively assess the impact of low insufflation pressure using AirSeal system (7mm Hg) during RAPN on post-operative patient pain (main location and intensity), 24 hours after surgery. The study will be conducted among 15 centers of the French research network on kidney cancer UroCCR.

NCT ID: NCT05403177 Recruiting - Breast Cancer Clinical Trials

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Start date: June 13, 2022
Phase:
Study type: Observational

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

NCT ID: NCT05400291 Recruiting - Bladder Cancer Clinical Trials

Gag-layer in the Urothelium of the Human Upper Urinary Tract

Start date: December 1, 2021
Phase:
Study type: Observational

Urothelial carcinomas of the lower and upper urinary tract can be considered "twin diseases". Much of the current clinical decision-making surrounding Upper Tract Urothelial Carcinoma (UTUC) is extrapolated from evidence that is based on urothelial carcinoma of bladder patients. The inner wall of the bladder is coated with a substance called glycosaminoglycan (GAG). GAG is known to form a gel-like layer on the apical cell membrane and act as a barrier against urine and pathogens in the lower urinary tract. Currently no published research on the presence of a GAG layer in the upper urinary tract exists. However, literature suggests that the ureteral utothelium can be transduced without enhancers, and the ureteral urothelium may be intrinsically different from bladder, both by the presence or absence of a GAG-layer, by different composition/thickness of the GAG-layer. Any functional differences between the urothelial layers in the bladder and in the upper urinary tract may affect the adeno-virus transduction, which again will have potential impact on future treatment of UTUC patients with a current unmet medical need.

NCT ID: NCT05387863 Not yet recruiting - Renal Cancer Clinical Trials

Decision Aid (DA) for Renal Patients

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.

NCT ID: NCT05377632 Not yet recruiting - Renal Tumor Clinical Trials

Comparing Two Different Approaches in Robotic-Assisted Renal Surgery

PIONEER-OPT
Start date: May 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the novel TR approach is superior to the standard RP approach. The anticipated study outcome is a time saving of at least 30% from first skin incision to detection of the renal artery compared to the conventional RP approach, and also a better workspace perception by the operating surgeon.

NCT ID: NCT05366881 Recruiting - Breast Cancer Clinical Trials

cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

CAMPERR
Start date: May 3, 2022
Phase:
Study type: Observational

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate). These cancers were selected based on the existing clinical landscape and treatment availability.

NCT ID: NCT05363657 Recruiting - Kidney Cancer Clinical Trials

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

i-RECORd
Start date: January 10, 2022
Phase:
Study type: Observational

Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors. In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs laparoscopic vs robotic) and resection techniques to different patient-, tumor-, and surgeon-specific characteristics. To meet the challenges, to overcome the limitations of current kidney cancer literature (such as the retrospective study design, potential risk of biases, and heterogeneous follow-up of most series), and to provide high-quality evidence for future development of effective clinical practice Guidelines, we designed the international REgistry of COnservative or Radical treatment of localized kiDney tumors (i-RECORD) Project. The expected impact of the i-RECORD project is to provide robust evidence on the leading clinical and environmental factors driving selection of the management strategy in patients with kidney cancer, and the differential impact of different management strategies (including AS, WW, AT, PN and RN) on functional, perioperative and oncological outcomes, as well as quality of life assessment, at a mid-long term follow-up (5-10 years).

NCT ID: NCT05363072 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Start date: May 9, 2022
Phase:
Study type: Observational

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.